Effects of endothelin-1 (ET-1) on ocular hemodynamics

What Was Tested

The paper reports a study of Endothelin-1, published as a randomized controlled trial.

There is evidence from in vitro and animal data that endothelin-1 (ET-1) plays an important role in ocular blood flow.

The aim of the present study was to investigate the effect of systemic ET-1 administration on ocular circulation in healthy subjects.

Who Took Part

The study group was 10 subjects.

PubMed indexes the participants as adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Endothelin-1 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Endothelin-1.

A placebo (an inactive look-alike) gave the Endothelin-1 group a baseline to be compared against.

In the crossover set-up each of the subjects took both Endothelin-1 and the comparison in turn, acting as their own control.

Blood flow velocity in the ophthalmic artery as well as ocular fundus pulsations in the macula and the optic disc, and systemic hemodynamic parameters were measured.

What Was Measured

PubMed files the paper under topics including Endothelin-1, Eye, Hemodynamics, Macula Lutea, Optic Disk, Pulse and Regional Blood Flow.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Endothelin-1 in 10 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Current eye research), a journal based in England.

More context: the Endothelin-1 compound page, all human trials.